Related Experiment Video
Updated: May 11, 2026
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Device Exchange to HeartMate 3 LVAD: Impact of Previous Pump Model on Clinical Outcomes
Laura Coyle1, Vinh Q Chau1,2, Colleen Gallagher1,2
1Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, Illinois.
Background:
We describe our clinical experience performing device exchange from a HeartMate II (HM2) or HVAD to a HeartMate 3 (HM3) left ventricular assist device.
Methods:
A single-center retrospective study was performed of all patients (N = 14) who underwent a left ventricular assist device exchange from HM2 (n = 7) or HVAD (n = 7) to HM3 between October 2018 and October 2021. The primary outcome was 1-year overall survival, and secondary outcomes included adverse events through discharge.
Results:
All patients (median age, 59 years; 29% female) were destination therapy and required urgent device exchange because of pump failure. Although statistically insignificant, the 1-year overall survival was worse in the HVAD to HM3 group compared with the HM2 to HM3 cohort (57% vs 100%, respectively; P = .19). The HVAD to HM3 group also experienced significantly more acute right-sided heart failure requiring right ventricular assist device support (71% vs 0%; P = .02), ventilator days (11 days vs 1 day; P = .001), and reoperation (100% vs 14%; P = .004).
Conclusions:
Patients being considered for device exchange from HVAD to HM3 may have a more complicated clinical course compared with HM2 to HM3 patients.
More Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
